This is a "connection" page, showing publications co-authored by Andrew Chapman and Ginah Nightingale.
Nightingale G, Mohamed MR, Holmes HM, Sharma M, Ramsdale E, Lu-Yao G, Chapman A. Research priorities to address polypharmacy in older adults with cancer. J Geriatr Oncol. 2021 Feb 12.
Nightingale G, Pizzi LT, Barlow A, Barlow B, Jacisin T, McGuire M, Swartz K, Chapman A. The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software. J Geriatr Oncol. 2018 Mar 03.
Nightingale G, Hajjar E, Pizzi LT, Wang M, Pigott E, Doherty S, Prioli KM, Swartz K, Chapman AE. Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer. J Geriatr Oncol. 2017 Jul; 8(4):296-302.
Nightingale G, Swartz K, Chapman AE. Reply to M.-E. Rougé Bugat et al. J Clin Oncol. 2015 Dec 1; 33(34):4124-5.
Nightingale G, Hajjar E, Guo K, Komura S, Urnoski E, Sendecki J, Swartz K, Chapman A. A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer. J Geriatr Oncol. 2015 Sep; 6(5):411-7.
Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015 May 1; 33(13):1453-9.
Lu-Yao G, Nightingale G, Nikita N, Keith S, Gandhi K, Swartz K, Zinner R, Sharma S, Kelly WMK, Chapman A. Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy. J Geriatr Oncol. 2020 Mar 18.
Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, Rebbeck TR, Chapman A, Kantoff PW, Cullen J, Gomella L, Kelly WK. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. Eur Urol. 2019 Aug 02.